The estimated Net Worth of Enrique A Conterno is at least $16.5 Million dollars as of 7 July 2023. Mr Conterno owns over 1,880 units of FibroGen Inc stock worth over $149,889 and over the last 15 years he sold FGEN stock worth over $14,752,141. In addition, he makes $1,641,769 as CEO & Director at FibroGen Inc.
Mr has made over 37 trades of the FibroGen Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 1,880 units of FGEN stock worth $5,264 on 7 July 2023.
The largest trade he's ever made was selling 56,261 units of FibroGen Inc stock on 8 March 2023 worth over $1,160,102. On average, Mr trades about 6,963 units every 64 days since 2010. As of 7 July 2023 he still owns at least 374,722 units of FibroGen Inc stock.
You can see the complete history of Mr Conterno stock trades at the bottom of the page.
Enrique A. Conterno is the CEO & Director at FibroGen Inc.
As the CEO & Director of FibroGen Inc, the total compensation of Mr Conterno at FibroGen Inc is $1,641,769. There are 5 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of $5,856,450.
Mr Conterno is 54, he's been the CEO & Director of FibroGen Inc since . There are 19 older and 3 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
Enrique's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO, CA, 94158.
Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff, and Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
FibroGen Inc executives and other stock owners filed with the SEC include: